Using X-ray crystallography in drug discovery

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 4, 2002, Pages 613-619

  Rowland, R Scott ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Macromolecular crystallography; Molecular modeling; Structure based drug design; Virtual screening

Indexed keywords

BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; LIGAND BINDING; MOLECULAR RECOGNITION; REVIEW; SCREENING; SPECTROSCOPY; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; ANIMAL; CRYSTALLIZATION; DRUG DESIGN; DRUG EFFECT; HUMAN; METHODOLOGY; PHARMACEUTICS; PHYSIOLOGY;

ANIMALS; BINDING SITES; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036651858     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Beddell CR, Goodford PJ, Norrington FE, Wilkinson S, Wootton R: Compound designed to fit a site of known structure in human haemoglobin. Br J Pharmacol (1976) 57:201-209.
2. Goodford P: Drug design by the method of receptor fit. J Med Chem (1984) 27:558-564.
3. Jhoti H: High-throughput structural proteomics using X-rays. Trends Biotechnol (2001) 19:S67-S71.
4. Klebe G, Mietzner T: A fast and efficient method to generate biologically relevant conformations. J Comput Aided Mol Des (1994) 8:583-606.
5. Rowland RS, Allen FH, Carson WM, Bugg CE: Preferred interaction patterns from crystallographic databases. In: Crystallographic and Modeling Methods in Molecular Design. Bugg CE, Ealick SE (Eds), Springer-Verlag, New York, NY, USA (1990):229-253.
6. Bruno IJ, Cole JC, Lommerse JP, Rowland RS, Taylor R, Verdonk ML: IsoStar: A library of information about non-bonded interactions. J Comput Aided Mol Des (1997) 11:525-537.
7. Klebe G: The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands. J Mol Biol (1994) 237:212-235.
8. Cambridge Structural Database: Cambridge Crystallographic Data Centre, Cambridge, UK. http://www.ccdc.cam.ac.uk/prods/csd/csd.html
9. Shoichet BK, Bussiere DE: The role of macromolecular crystallography and structure for drug discovery: Advances and caveats. Curr Opin Drug Discovery Dev (2000) 3:408-422.
10. Ealick SE, Rule SA, Carter DC, Greenhough TJ, Babu YS, Cook WJ, Habash J, Helliwell JR, Stoeckler JD, Parks RE Jr et al. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. J Biol Chem (1990) 265:1812-1820.
11. Renatus M, Bode W, Huber R, Sturzebecher J, Stubbs MT: Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: Implications for the inhibition of factor Xa, tPA, and urokinase. J Med Chem (1998) 41:5445-5456.
12. Böhm M, Stürzebecher J, Klebe G: Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem (1999) 42:458-477.
13. Lipinski CA, Lombardo F, Dominy BW, Feeny PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (1997) 23:3-25.
14. Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods (2000) 44:235-249.
15. Navia MA, Chaturvedi PR: Design principles for orally bioavailable drugs. Drug Disc Today (1996) 1:179-189.
16. Walters WP, Murcko MA: Prediction of 'drug-likeness'. Adv Drug Deliv Rev (2002) 54:255-271.
17. Clark DE: Computational methods for the prediction of ADME and toxicity. Adv Drug Deliv Rev (2002) 54:253-254.
18. Klabunde T, Petrassi HM, Oza VB, Raman P, Kelly JW, Sacchettini JC: Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol (2000) 7:312-321. An application of structure-based drug design to stabilize quaternary structure is described and illustrates a fully evolved design cycle.
19. Petrassi HM, Klabunde T, Sacchettini J, Kelly JW: Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J Am Chem Soc (2000) 122:2178-2192.
20. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol (2002) 9:268-272. The combined use of screening and structure-based drug design is used to identify a novel binding site.
21. Böhm H-J, Klebe G: What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs? Angew Chem Int Ed Engl (1996) 35:2588-2614.
22. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW: Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 274:1531-1534.
23. Mattos C, Ringe D: Locating and characterizing binding sites on proteins. Nat Biotechnol (1996) 14:595-599.
24. Allen KN, Bellamacina CR, Ding X, Jeffery CJ, Mattos C, Petsko GA, Ringe D: An experimental approach to mapping the binding surfaces of crystalline proteins. J Phys Chem (1996) 100:2605-2611.
25. English AC, Done SH, Caves LSD, Groom CR, Hubbard RE: Locating interaction sites on proteins: The crystal structure of thermolysin soaked in 2% to 100% isopropanol. Proteins (1999) 37:628-640.
26. English AC, Groom CR, Hubbard RE: Experimental and computational mapping of the binding surface of a crystalline protein. Protein Eng (2001) 14:47-59.
27. Klebe G, Bohm HJ: Energetic and entropic factors determining binding affinity in protein-ligand complexes. J Recept Signal Transduction Res (1997) 17:459-473. A review of the many factors involved in molecular recognition.
28. Iversen LF, Andersen HS, Moller KB, Olsen OH, Peters GH, Branner S, Mortensen SB, Hansen TK, Lau J, Ge Y, Holsworth DD, Newman MJ, Hundahl Moller NP: Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases. Biochemistry (2001) 40:14812-14820.
29. Raman CS, Li H, Martasek P, Southan G, Masters BS, Poulos TL: Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry (2001) 40:13448-13455.
30. Kenny BA, Bushfield M, Parry-Smith DJ, Fogarty S, Treheme JM: The application of high-throughput screening to novel lead discovery. Prog Drug Res (1998) 51:245-269.
31. Broach JR, Thomer J: High-throughput screening for drug discovery. Nature (1996) 384:S14-S16.
32. Kuntz ID: Structure-based strategies for drug design and discovery. Science (1992) 257:1078-1082.
33. Walters WP, Stahl MT, Murcko MA: Virtual screening - an overview. Drug Disc Today (1998) 3:160-178.
34. Klebe G: Recent developments in structure-based drug design. J Molecular Med (2000) 78:269-281.
35. Murcko MA: An introduction to de novo ligand design. In: Practical Application of Computer-Aided Drug Design. Charifson PS (Ed), Marcel Dekker Inc, New York, NY, USA (1997):304-354.
36. Doman TN, McGovem SL, Witherbee BJ, Kasten TP, Kurumbail R, Stallings WC, Connolly DT, Shoichet BK: Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem (2002) 45:2213-2221.
37. McGovem SL, Caselli E, Grigorieff N, Shoichet BK: A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem (2002) 45:1712-1722. This study investigates the possible causes of promiscuous inhibitors, an important problem encountered in high-throughput screening.
38. Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J: Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol (2000) 18:1105-1108. This study illustrates the direct use of crystals for lead generation and optimization.
39. Nishibata Y, Itai A: Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation. J Med Chem (1993) 36:2921-2928.
40. Pearlman DA, Murcko MA: CONCERTS: Dynamic connection of fragments as an approach to de novo ligand design. J Med Chem (1996) 39:1651-1663.
41. Clark DE, Frenkel D, Levy SA, Li J, Murray CW, Robson B, Waszkowycz B, Westhead DR: PRO-LIGAND: An approach to de novo molecular design. 1. Application to the design of organic molecules. J Comput Aided Mol Des (1995) 9:13-32.
42. Bohm HJ: LUDI: Rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des (1992) 6:593-606.
43. Honma T, Hayashi K, Aoyama T, Hashimoto N, Machida T, Fukasawa K, Iwama T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Iwasawa Y, Hayama T, Nishimura S, Morishima H: Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design. J Med Chem (2001) 44:4615-4627.
44. Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N, Fukasawa K, Takaki T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Hayama T, Nishimura S, Morishima H: A novel approach for the development of selective Cdk4 inhibitors: Libray design based on locations of Cdk4 specific amino acid residues. J Med Chem (2001) 44:4628-4640.
45. Beavers MP, Chen X: Structure-based combinatorial library design: Methodologies and applications. J Molecular Graphics Modelling (2002) 20:463-468. Comprehensive review of the combined application of combinatorial chemistry and structure-based drug design with numerous examples.
46. Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS: Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. J Med Chem (2002) 45:2016-2023.
47. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin TH, Hutchison TL, Elliott AJ, Parker CD, Ananth SL, Hom LL, Laver GW, Montgomery JA: BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem (2000) 43:3482-3486.
48. Chand P, Kotian PL, Dehghani A, El-Kattan Y, Lin TH, Hutchison TL, Babu YS, Bantia S, Elliott AJ, Montgomery JA: Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J Med Chem (2001) 44:4379-4392.
49. ABBOTT LABORATORIES (Nienaber VL, Greer J, Abad-Zapatero C, Norbeck DW): Ligand screening and design by X-ray crystallography. WO-09945379 (1999).
50. ABBOTT LABORATORIES (Nienaber VL, Greer J, Abad-Zapatero C, Norbeck DW): Ligand screening and design by X-ray crystallography. WO-09945389 (1999).